Based on this, STM418, a monoclonal antibody targeting the N58 glycosylation site of PD-1 was developed, exhibited a higher binding affinity for PD-1 than FDA-approved nivolumab and pembrolizumab, effectively inhibiting PD-1/PD-L1 binding and enhancing anti-tumor immunity [46]. This evidence concerns the gene PDCD1 and neoplasm.